Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studies
Background and objectives: Although amyloid positron emission tomography (PET) and Cerebrospinal fluid (CSF) biomarkers remain the standard for confirming Alzheimer’s disease (AD) pathology, their use is impractical for screening or routine prognostic assessment. Plasma phosphorylated tau […]
Cognitive performance and blood biomarkers: Insights into their relationship and predicting high Amyloid Probability Score in cognitively impaired older adults
Background: Understanding associations between cognitive performance and blood biomarkers supports diagnosis and treatment of Alzheimer’s disease (AD); however, this relationship remains unclear. Objective: Exploring associations between the Amyloid Probability Score (APS; PrecivityAD® blood test) and cognitive […]
COVID-19 Pandemic-Related Exposures and Cognitive Function in Middle-Aged Women
Importance: The COVID-19 pandemic has been associated with risk factors for cognitive decline, such as bereavement and SARS-CoV-2 infection. Objective: To examine whether the COVID-19 pandemic and pandemic-related exposures are associated with cognitive function among middle-aged […]
Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease
Background and Objectives In early Alzheimer disease (AD), β-amyloid (Aβ) deposition is associated with volume loss in the basal forebrain (BF) and cognitive decline. However, the extent to which Aβ-related BF atrophy manifests as cognitive decline […]
Post-traumatic stress disorder symptom remission and cognition in a large cohort of civilian women
Background Post-traumatic stress disorder (PTSD) is associated with cognitive impairments. It is unclear whether problems persist after PTSD symptoms remit. Methods Data came from 12 270 trauma-exposed women in the Nurses’ Health Study II. Trauma and […]
